Recombinant human erythropoietin (r-HuEPO) therapy in a newborn with hereditary spherocytosis;Utilisation de l'érythropoïétine chez un nouveau-né atteint de sphérocytose héréditaire

Archives de Pediatrie

Volumn 10, Issue 4, 2003, Pages 333-336

  Schiff, M ^a   Hays S ^a   Sann, L ^a   Putet, G ^a  

^a HÔPITAL DEBROUSSE   (France)

Author keywords

Erythropoietin recombinant; Infant, newborn; Spherocytosis hereditary

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CASE REPORT; ERYTHROCYTE TRANSFUSION; HEREDITARY SPHEROCYTOSIS; HUMAN; INFANT; JAUNDICE; NEWBORN; NEWBORN PERIOD;

EID: 0038790215     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(03)00043-5     Document Type: Article

References (12)

1. Delaunay J. Anémies hémolytiques d'origine membranaire. Hématologie. Paris: Encycl Méd Chir (Elsevier); 1999 13-006-D-05.
2. Iolascon A, Miraglia Del Giudice E, Perrotta S, Alloisio N, Morlé L, Delaunay J. Hereditary spherocytosis: from clinical to molecular defects. Haematologica 1998;83:240-57.
3. Hassoun H, Palek J. Hereditary spherocytosis: a review of the clinical and molecular aspects of the disease. Blood Rev 1996;10:129-47.
4. Cynober T, Mohandas N, Tchernia G. Red cell abnormalities in hereditary spherocytosis: Relevance to diagnosis and understanding of the variable expression of clinical severity. J Lab Clin Med 1996; 128:259-69.
5. Delhommeau F, Cynober T, Schischmanoff PO, Rohrlich P, Delaunay J, Mohandas N, et al. Natural history of hereditary spherocytosis during the first year of life. Blood 2000;95:393-7.
6. Miraglia Del Giudice E, Nobili B, Francese M, D'Urso L, Iolascon A, Eber S, et al. Clinical and molecular evaluation of non-dominant hereditary spherocytosis. Br J Haematol 2001;112:42-7.
7. Bolton-Maggs PH. The diagnosis and management of hereditary spherocytosis. Baillieres Best Pract Res Clin Haematol 2000;13: 327-42.
8. Miraglia Del Giudice E, Perrotta S, Lombardi C, Iolascon A. Decision making at the bedside: diagnosis of hereditary spherocytosis in a transfused infant. Haematologica 1998;83:347-9.
9. Delhommeau F, Cynober T, Mielot F, Schischmanoff PO, Delaunay J, Mohandas N, et al. Hereditaryspherocytosis in newborns and infants: biological diagnosis and preliminary results of Rh-EPO treatment (abstract). Blood 1996;88(suppl. 1., pt2):139b.
10. Tchernia G, Delhommeau F, Perrotta S, Cynober T, Bader-Meunier B, Nobili B, et al. Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis. Hematol J 2000;1:146-52.
11. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New Engl J Med 2002;346:469-75.
12. Zipursky A. The risk of hematopoietic growth factor therapy in newborn infants. Pediatr Res 2002;51:549.